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Abstract
Allelic variation of apolipoprotein E (apo E) has been shown to infl uence the concentrations of total 
cholesterol and low density lipoprotein cholesterol (LDL-C) and considered to play a role as one of risk 
factors for coronary heart disease (CHD). The aim of this study was to examine the relationship between Apo 
E polymorphism and the risk of CHD. Blood samples were collected from 33 CHD patients in Dr. Sardjito 
Hospital Yogyakarta, and 38 apparently healthy control individuals in a cross sectional study. The common 
allelic variants of ApoE were screened employing polymerase chain reaction and restriction fragment length 
polymorphism. The results obtained were analyzed by t-test and signifi cantly different if p <0.05 and risk 
factor was calculated by odd ratio. Frequency of ApoE ε2, ε2 and ε4 alleles in CHD patients were  12.1%, 69.7% 
and 18.2% while in controls were 18.4%, 72.4% and 9.2% respectively. Dyslipidemia condition was a strong 
risk factor for CHD. By controlling lipid profi le and applying multifactorial statistic analysis, it was shown 
that ε4 gene carrier was the risk factor for CHD, but not in triglyceride level, whereas ε2 carrier gene was not 
the risk factor for CHD. Dislipidemia was the risk factor for CHD and ApoE ε4  gene carrier was the risk factor 
for CHD.
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Introduction
Apolipoprotein E (apoE) is a protein 
constituent of plasma lipoproteins that 
performs several functions including a role in 
cholesterol metabolism and as an important 
ligand in lipoprotein clearance. Apolipoprotein 
E was fi rst identifi ed as a constituent of very 
low density lipoprotein (VLDL) which 
function to transport triglycerides from the 
liver to peripheral tissues (Mayes and Botham, 
2006). Apolipoprotein E gene is polymorphic 
and exists in six different isoform proteins, 
designated E2/E2, E2/E3, E2/E4, E3/E3, E3/
E4, and E4/E4 which are the gene products of 
three ApoE alleles i.e. ε2, ε3 and ε4 respectively 
(Belkovets et al., 2001). Apolipoprotein E2 
exhibits lower affi nity for the LDL receptor, 
resulting in slower clearance of ApoE and 
higher plasma apoE levels. Conversely, 
ApoE4 is cleared more effi ciently, resulting 
in lower ApoE levels and higher cholesterol 
levels. The genetic variations thus affect lipid 
metabolism and have been shown to alter 
risk of cardiovascular disease and dementia 
(Eichner et al., 2002).
Epidemiologic studies addressing the 
contribution of apo ε gene to Coronary Heart 
Disease (CHD), reported that 6 percent of the 
variation in risk for CHD in North America 
can be attributed to this locus. Another study 
of middle-aged men from nine populations 
estimated a 40 percent increased risk for 
CHD mortality for ε4 carriers compared with 
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ε3  carriers or ε2 carriers (Stengard et al., 1998). 
Some studies have also suggested that ε4 
carriers are particularly prone to developing 
disseminated coronary lesions or to have an 
increased risk of death from CHD (Eichner 
et al., 1993, Lehtinen et  al., 1995; Stengard et 
al., 1995, Wang et al., 1995). Coronary heart 
disease is related to dysfunction of the E4 
isoform in lipoprotein metabolism and an 
increased concentration of serum cholesterol 
and triglycerides. Studies from Finland, 
Scotland, and northern part of Ireland 
have shown that populations with higher 
cholesterol levels and higher CHD mortality 
rates also have a higher frequency of the ε4 
allele. Other studies have also associated the 
ε2 allele with increased CHD risk (Eichner 
et al., 2002, Zannis et al., 1996, Mahley et al., 
2006).
An association between apoE ε2/ε2 
and type III hyperlipoproteinemia has 
been known for decades. This disorder is 
characterized by increased cholesterol and 
triglyceride levels, the presence of ß-VLDL 
(cholesterol-enriched remnants of intestinal 
chylomicrons and hepatic VLDL), xanthomas, 
and premature vascular disease, both CHD 
and peripheral artery disease (Mahley et 
al., 1995). Overt hyperlipoproteinemia III 
occurs with a frequency of 1–5 per 5,000, 
whereas homozygosity for E2/2 occurs with 
a frequency of 0.5–1.0 per 100 in Caucasian 
populations. Thus, this genotype contributes 
to the hyperlipoproteinemia III phenotype 
without being its sole cause (Eichner et al., 
2002, Fullerton et al., 2000). It examines the 
relationship of this genotype in CHD patients 
compared to the specifi ed controls.
Materials and Methods
 Blood samples were collected from 
CHD patients in Dr. Sardjito Hospital 
Yogyakarta compared with controls collected 
from an exersice group in Yogyakarta. 
Inclusion criteria: patients were 
diagnosed by an Internal Medicine Specialist 
as CHD, Javanese male or female age 40 – 
75 years, BMI <30, and free from Diabetes 
Mellitus (DM). Exclusion criteria: CHD 
patients with DM and non Javanese ethnic 
background. Inclusion criteria for the control 
group: apparently healthy male or female 
individuals, BMI < 30, no DM, age 40 – 75 
years and Javanese ethnic in origin. Exclusion 
criteria: DM and non Javanese.
Plasma from patients and controls 
were separated and their lipid profi les were 
examined. Buffy coat from patients and controls 
were prepared for DNA isolation. Polymerase 
Chain Reaction (PCR) was performed with 
Zivelin et al., (1997) method to amplify exon 
4 and then followed by HaeII dan Afl III 
digestion to identify the ε2, ε3 and ε4 allele with 
195 and 23 bp for ε4; 23, 50 and 145 bp for ε3 
and 50 and 168 bp for ε2 respectively. Genotype 
of ε2/ε2 and ε2/ε3 were grouped as ε2 carrier; 
genotype of ε3/ε3 was grouped as ε3 carrier 
and genotype of ε3/ε4 and ε4/ε4 were grouped 
as ε4 carrier. ApoE ε2/ε4 was not included as 
any apoE carrier. The result was analyzed 
employing t-test to compare lipid profi le in 
CHD patients and controls with signifi cant 
difference at p <0.05.  Odd Ratio was used to 
determine the risk factors, while Chi Square 
test was used for frequency of apoE genotype 
and allele as risk factor of CHD. Another Odd 
Ratio was apllied to analyse apoE genotype 
and allele as risk factor of CHD with controlled 
lipid profi le.
Results
Apolipoprotein E polymorphism was 
examined in 33 CHD patients and 38 controls. 
There were no signifi cant difference between 
patients and controls in the body weight, 
height, BMI, blood pressure and blood 
glucose with t-test p>0.05 (Table 1). 
There were no significant difference 
between CHD patients and controls in their 
lipid profi le (p>0.05) despite higher levels 
of triglyceride, cholesterol, and LDL-C and 
lower level of HDL-C in CHD patients (Table 
2 and Figure 1).
When Chi  square  analysis  was 
employed, higher frequency of dyslipidemia 
in CHD patients was observed with 
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Table 2.  Lipid profi le in CHD patients and controls 
CHD (n = 33) Control (n = 38) P
Triglyceride (mg/dL) 136.8 ± 56.6 123.47 ± 63.98 0.680
Cholesterol total (mg/dL) 196.1 ± 37.3 169.9 ± 39.4 0.657
LDL-C (mg/dL) 121.8 ± 37.3  102.69 ± 50.16 0.527
HDL-C (mg/dL) 44.8 ± 12.5 49.6 ± 10.1 0.256
Figure 2. PCR result of apoE (218 base pair) (1, 5, 69, 
74, 92, 98 and 100 were PCR result with 218 bp, WC 
was water control, M = marker Φx174)
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Figure 3. Result of PCR after digested by Afl  III and 
Hae II enzymes (No 2, 4, 7, 9, 11, 12, 16  were E ε3-3 
genotype, no 3 and 8 were apoE ε3-4 genotype, no 10 was 
apoE ε2-3 genotype, no 20 was apoE ε2-2 geneotype, and 
M was marker Φx174).  
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Figure 1. Lipid profi les in CHD and control
Table 1. Sex, age, body weight, height, blood pressure, and blood glucose level in CHD 
patients and control
CHD patients
(n = 33)
Control
(n=38) P
Men
Women
Age (year) 
20
13
60.5 ± 9.2
22
16
57.9 ± 8.60
0.992
0.843
Body Weight (kg) 63.23 ± 9.26 62.56 ± 9.30 0.754
Height (m) 1.62 ± 0.05 1.61± 0.053 0.400
BMI (kg/m2) 24.01 ± 3.08 24.0 ± 3.35 0.989
Systolic BP (mmHg) 141.0 ± 17.88 137.31 ± 19.56 0.394
Dyastolic BP (mmHg) 84.0 ± 10.70 89.04 ± 12.96 0.069
Blood glucose (mg/dL) 112.4 ± 14.70 104.3 ± 12.5 0.086
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Table 3. Odd Ratio of lipid  profi le between CHD and controls
CHD
N = 33
CONTROL
N = 38 OR (Cl 95%)
Cholesterol >200 mg/dL
                 < 200 mg/dL
14
19
6
32
3.93 (1.15 – 13.5)
Triglyceride > 150 mg/dL
                   < 150 mg/dL
11
22
10
28
1.40 (0.45 – 4.40)
HDL-C < 40 mg/dL
             > 40 md/dL 
12
21
6
32
3.05 (0.88 – 10.94)
LDL-C > 130 mg/dL
            < 130 mg/dL 
12
21
10
28
1.60 (0.52 – 4.98)
Table 4. Polymorphism of apoE in CHD and control
CHD (33) Control (38) OR (Cl 95%) P
Genotype ɛ2/ɛ2 : 1 (3.1%)
ɛ2/ɛ3 : 6 (18.1%)
ɛ2/ɛ4 :        -
ɛ3/ɛ3 :14 (42.4%)
ɛ3/ɛ4 :12 (36.4%)
ɛ4/ɛ4 :        - 
ɛ2/ɛ2 : 4 (10.5%)
ɛ2/ɛ3 : 5 (13.2%)
ɛ2/ɛ4 : 1 (2.6%)
ɛ3/ɛ3 : 23 (60.6%)
ɛ3/ɛ4 : 4 (10.5%)
ɛ4/ɛ4 : 1 (2.6%)
0.26 (0.01 – 2.68)
1.47 (0.34 – 6.36)
-
1.00
4.86 (1.22 – 20.83) 
-
0.082
Gene carrier ε2 : 7 (21.2%)
ε3 : 14 (42.4%)
ε4 : 12 (36.4%)
 ε2 : 9 (24.3%)
 ε3 : 23 (62.2%)
 ε4 : 5 (13.5%)
1.28 (0.40 -4.07)
1.00
3.94 (0.99 – 16.48)
0.078
Alelle ε2 : 8 (12.1%)
ε3 : 46 (69.7%) 
ε4 : 12 (18.2%) 
 ε2 : 14 (18.4%)
 ε3 : 55 (72.4%) 
 ε4 : 7 (9.2%) 
0.68 (0.24 -1.94)
1.00
2.05 (0.68 – 6.35)
0.216
signifi cant difference (p<0.05) in cholesterol 
concentrat ion.  Applying Odd Ratio 
calculation, it was showed that dyslipidemia 
was a strong risk factor for CHD with 1.4 – 
3.93 times higher (Table 3)
The result of PCR (Figure 2) was 
digested by Afl  III and Hae II to determine 
the apoE ε2, apoE ε3, and apoE ε4 genotypes 
(Figure 3).
The frequency of apoE ε2/ε2, apoE ε2/
ε3, apoE ε3/ε3, and apoE ε3/ε4 genotypes in 
CHD patients were  3.1%, 18.1%, 42.4% and 
36.4%, respectively and in controls were 
10.5%, 13.2%, 60.6%, and 15.7%. ApoE ε2/ε4 
and apoE ε4/ε4 genotypes were not found in 
CHD patients. Comparison was not possible. 
Significant difference (p<0.05) was only 
observed in apoE ε3/ε4 genotype with OR 4.86 
times higher than other genotypes between 
CHD patients and controls. Apolipoprotein E 
ε2/ε2 genotype in CHD patients showed OR 
< 1, indicating that  apoE ε2/ε2 genotype was 
protective factor for CHD (Table 4).
On the other hand, despite p>0.05 for ε4 
allele, OR 2.05 indicates its role as risk factor 
for CHD. It can be summarized that apoE ε3/
ε4 genotype and ε4 allele were risk factors for 
CHD, whereas apoE ε2/ε2  genotype and ε2 
allele were protective factors for CHD. 
Be ing  as  r i sk  fac tor  for  CHD, 
dyslipidemic condition especially the increase 
of cholesterol and LDL-C as well as the 
decrease of HDL-C levels were risk factors 
for CHD for all of apoE genotypes (Tabel 5, 6, 
and 7). In contrast, the increase of triglyceride 
level in ε2 carrier gene was not the risk factor 
for CHD (Table 8). 
Table 5 showed the relation of apoE 
polymorphism with hypercholesterolemia 
which is 5 and 7.88 times higher to have CHD 
in high concentration of cholesterol but in the 
case of ε4 carrier the OR of this gene carrier 
could not be calculated due to low level of 
cholesterol in the control group. This result 
summarized that hypercholesterolemia 
caused CHD in all of apoE gene carrier. 
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Table 6. Risk factor of ApoE polymorphism in LDL-C 
level in CHD patients and Control 
ApoE gene 
carrier 
CHD 
patients Control OR (Cl95%)
LDL-C
ε2,  > 130 mg/dL
ε2,  < 130 mg/dL
5
2
3
6
5.00 (0.4 – 81.88)
ε3, > 130 mg/dL
 ε3, < 130 mg/dL
2
12
5
18
 0.60 ( 0.07 – 4.51)
ε4,  > 130 mg/dL
ε4, < 130 mg/dL
5
7
1
4
2.86 (0.17 – 90.96)
Table 6 showed that high level of LDL-C 
was risk factor for CHD with ε2 and ε4 alleles, 
but not for ε3 allele. In low HDL-C level, 
individual with ε2 and ε3 alleles were at risk 
for CHD (Table 7).
Table 7. Risk factor for apoE polymorphism in HDL-C 
level in CHD patients and control
ApoE carrier 
genee CHD Control OR (Cl 95%)
HDL-C
ε2, < 40 mg/dL
ε2, > 40 mg/dL
3
4
1
8
6.00 (0.33 – 214.95)
ε3, < 40 mg/dL
 ε3, > 40 mg/dL
6
8
3
20
5.00 (0.80 – 34.52)
ε4, < 40 mg/Dl
ε4, > 40 mg/dL
3
9
1
4
1.33 (0.07 – 45.29)
Table 8 showed that high level of 
triglyceride was the risk factor for CHD with 
ε3 and ε4 alleles, but not for ε2 allele. 
The overall OR of lipid profi le showed 
ε2 carrier of apoE gene was the risk factor 
for CHD provided that the respective 
individuals have high cholesterol and low 
HDL-C level. Similarly, carrier of ε3 and ε4 
Table 5. Risk factor of apoE polymorphism to high level of cholesterol in CHD 
patients and control 
ApoE gene carrier CHD patients Control OR (Cl 95%)
CHOLESTEROL
ε2,  > 200 mg/dL
ε2,  < 200 mg/dL
5
2
3
6
5.00 (0.40 – 81.88)
ε3,  > 200 mg/dL
  ε3, < 200 mg/dL
6
8
2
21
7.88 (1.06 – 72.78)
ε4,  > 200 mg/dL
ε4,  < 200 mg/dL
4
8
0
5
-
Table 8. Risk factor for ApoE polymorphism in 
triglyceride level in CHD patients and control
ApoE gene 
carrier 
CHD 
patients Control OR (Cl 95%)
TRIGLYCERIDE
ε2, > 150 mg/dL
ε2, < 150 mg/dL
1
6
8
1
0.04 (0,00–0.58)
ε3, > 150 mg/dL
ε3, < 150 mg/dL
6
8
0
23
-
ε4, > 150 mg/dL
ε4, < 150 mg/dL
4
8
1
4
2.00 (0.11–64.91)
Table 9. The role of ApoE polymorphism as the risk 
factor for CHD with controlled lipid profi le. 
Carrier of ApoE gene OR 95% CI
Gene ε2
Gene ε3
Gene ε4
1.278
1.000
4.025
0.406 – 4.020
-
1.207 – 13.418
Triglyceride
Gene ε2
Gene ε3
Gene ε4
1.016
0.644
1.000
1.016
1.006 – 1.027
0.168 – 2.470
-
1.095 – 14,265
Cholesterol
Gene ε2
Gene ε3
Gene ε4
1.017
0.957
1.000
4.003
1.003 – 1.030
0.277 – 3.301
-
1.140 -14.052
HDL-C
Gene ε2
Gene ε3
Gene ε4
0.951
1.126
1.000
4.336
0.908 – 0.996
0.348 – 3.649
-
1.225 – 15.350
LDL-C
Gene ε2
Gene ε3
Gene ε4
1.013
1.117
1.000
4.119
1.000 – 1.026
0.333 – 3.743
-
1.197 – 14.165
apoE gene were also at risk of CHD in the 
presense of dyslipidemia with high levels 
of triglycerides, total cholesterol and LDL-C 
and low level of HDL-C.
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This study was designed as a case 
control study without special treatment to 
control lipid profi le in both groups which was 
later controlled by multifactorial analysis. 
Table 9 showed even in controlled lipid 
profi le, ε4 gene carrier has the risk factor for 
CHD 3.94 times higher except in triglyceride 
level, while the ε2 gene carrier was not the 
risk factor for CHD with OR <1. 
Discussion
To demonstrate the role of ApoE 
polymorphism as the risk factor for CHD,  the 
frequency of ApoE gene in CHD patients was 
compared with controls. It was shown that 
ε2 allele was the protective factor for CHD 
and ε4 allele was the risk factor for CHD. This 
risk factor was not different in other world 
populations, in which ε4 gene was the risk 
factor for CHD than those ε2 and ε3 genes 
(Eichner et al., 2002; Elousa et al., 2004; Mahley 
et al., 2006; Mc. Neale et al., 2000; Pirim et al., 
2001). This ε4 gene was also the risk factor 
for myocard infarc, atherosclerosis, stroke, 
and neurodegeneration (Elousa et al., 2004; 
Frikke-Schmidt et al., 2000 (a); Guera et al., 2003; 
Leshinsky-Silver et al., 2006; Mahley et al., 2006; 
Masemola et al., 2007; Moghadasian  et al., 2001; 
Sheehan et al., 2000; Sima et al., 2006; Yang et 
al., 2004). Population with high frequency of 
ε4 allele have high incidence of ischemic heart 
disease and this genetic determinant was 
related to mortality in isolated populations 
(Garces et al., 2004). Different result were found 
in China, where polymorphism of ε4 gene was 
not the risk factor for CHD (Liu et al., 2003), 
as well as in coronary artery disease. This ε4 
gene was not the risk factor in Oman, Greek 
and Brazalian populations (Al-Yahyaee et al., 
2007; De Franca et al., 2004; Kolovou et al., 2002; 
Souza et al., 2007)
The role of apoE polymorphism in 
causing dyslipidemia was studied in CHD 
patients and controls. Apolipoprotein ε2 allele 
has protective effect for CHD, but ε3 and ε4 
alleles were the risk factor for CHD especially 
in individuals with dyslipidemia. The role 
of apoE polymorphism on dyslipidemia in 
Indonesian populations seems to be almost 
similar to that in the world’s populations in 
which the ε2 allele was the protective factor 
for CHD despite suffering  from dyslipidemia 
(Chaaba et al., 2009; Chanprasetyothin et al., 
2000; Eichner et al., 2002; Elousa et al., 2004; 
Mahley et al., 2006; Masemola et al., 2007; 
Moghadasian et al., 2001;  Rodsari et al., 2005; 
Sheehan et al., 2000; Yang et al., 2004; Zannis et 
al., 1996). Other studies reported that ε2 allele 
was related with high triglyceride level and 
the incidence of type III hyperlipoproteinemia 
(Batal et al., 2000; Bennet et al., 2007; Eichner 
et al., 2002; Letonja et al., 2004; Liberopoulos 
et al., 2004; Pallaud et al., 2001). 
The role of apoE polymorphism in 
causing dyslipidemia is due to the ability 
of apoE3 to accept more cholesterol from 
fi broblast than apoE2 and apoE4 (Huang et al., 
2009). In HDL3,  apoE3 binds cholesterol better 
than apoE4, because the structure of carbon 
end domain of apoE4  was irregular and more 
exposed to the water; these differences causes 
the pathologically of cardiovascular and 
neurodegenerative disease (Sakamoto et al., 
2008). These conditions showed that genetic 
factors and lipid profi le varies with age, sex, 
and the differences of environmental factors 
(Pallaud et al., 2001). Studies by Eichner et al., 
(2002), giving hypolipidemic drugs to block 
HMG-CoA reductase or drugs to reduce 
lipid profi les, was effective for apoE ε2 and 
apoE ε3 gene carriers, but apoE ε4 gene carrier 
was difficult to be influenced by medical 
intervention. Low lipid and cholesterol diets 
induced the decrease of cholesterol and 
LDL levels higher in apoE ε4 gene carrier 
than in apoE ε2 and apoE ε3 gene carriers. It 
was shown that response to hypolipidemic 
drugs was different in apoE polymorphism. 
Treatment with phenofi brate showed that 
ε2 allele reduce lower in triglyceride level 
than others (Irvin et al., 2010). The defect 
in E4 protein, causes effi cacy to bind and 
transport of lipid decrease. Statin drug to 
decrease lipid profi les was not responded by 
some individuals because of high response 
variability of hypolipidemic drugs. It can 
I.J. Biotech.
48
Hastuti et al.
be summarized that the detection of genetic 
variability that infl uence lipoprotein levels 
in the plasma supports to predict therapeutic 
response (Morrison, 2007). The ε4 allele is 
consistently lower in reduced cholesterol 
level after hypolipidemic therapeutic in 
Portugese (Withers, 2011). Regarding the 
effect of therapeutic intervention to modify 
the disease related with apoE polymorphism, 
apoE ε4 gene carrier had the worst effect 
(Cacabelos et al., 2010)
 As conlusion, dyslipidemia was the risk 
factor for CHD. Apolipoprotein E ε3/ε4 genotype 
and ε4 allele were the risk factor for CHD 
whereas apoE ε2/ε2 genotype and ε2 allele were 
protective factor for CHD. Polymorphism of 
apoE led to variability of triglyceride level but 
not causes variability of other lipid profi le. 
Apolipoprotein E ε3/ε4 genotype and ε4 allele 
were the risk factor for CHD.
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